Embedded Files
LATEST FROM COOL FLAME BIO
2026
Dr. Bob Dworkin PhD, Professor of Anesthesiology and Perioperative Medicine and Professor of Neurology at the University of Rochester School of Medicine joins Cool Flame Bio's Scientific Advisory Board. Dr. Dworkin is an industry veteran in the development of clinical trials and research into chronic and acute neuropathic pain.
FDA accepts pIND package. CFB moves forward for full IND package development for FIH studies in CIPN for later this year.
CFB submits additional US and international patents pending on the preservation of chemotherapy based on the reduction of CIPN dose limiting toxicity.
2025
CFB team submits pIND package to FDA for First in Human (FIH) studies in CIPN.
Dr. Robert Allen MD, subject matter expert in neurology and pain management drug development, joins CFB as an advisor.
Cool Flame Bio partners with City of Hope advisors Drs. Ed Kim MD and Rich Lee MD.
CFB completes initial toxicology package for CFB-001 with excellent safety profile.
Cool Flame Bio demonstrates early pre-clinical proof of concept with mitochondrial protection followed by neuroprotection and neurosalvage.
CFB-001 product is shown to be compatible with platinum-based chemotherapy and does not interfere with multiple cancer cell lines nor the effects of the chemotherapy. Furthermore, CFB-001 does not interfere with cancer metastases.
CFB in licenses Intellectual Property (IP) for CFB-001 platform for the topical treatment of peripheral neuropathies. Focuses on Chemotherapy Induced Peripheral Neuropathy (CIPN) as first target.
Cool Flame Bio (CFB) was founded by a seasoned drug development team working with mitochondrial stabilizers for the past five years in the retina space.
Report abuse